Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | F11 | P03951 | 2/20 | 0.47 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HMGCR | P04035 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294666 | 1.00 | PTPN1 (0.52) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL18068236 | 0.96 | PTPN1 (0.56) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL22455860 | 0.96 | PTPN1 (0.56) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL17850298 | 0.96 | PTPN1 (0.56) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL14428922 | 0.96 | PTPN1 (0.56) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL13250762 | 0.96 | PTPN1 (0.56) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL14405192 | 0.96 | PTPN1 (0.56) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL20730007 | 0.96 | PTPN1 (0.56) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL13271795 | 0.96 | PTPN1 (0.56) | PTPN1USP2MEN1POLBKMT2A | |
| SCHEMBL13250766 | 0.96 | PTPN1 (0.56) | PTPN1USP2MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267940-A1 | Method for Producing 4-Deoxy-4-Fluoro-D-Glucose Derivative | CENTRAL GLASS COMPANY, LIMITED (JP) | 2010-10-21 | — | — | US | claimed |
| EP-2216337-A1 | METHOD FOR PRODUCING 4-DEOXY-4-FLUORO-D-GLUCOSE DERIVATIVE | Central Glass Company, Limited (JP) | 2010-08-11 | — | — | EP | claimed |
| US-8845999-B2 | Tracers for monitoring the activity of sodium/glucose cotransporters in health and disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| EP-2482823-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI (FR) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039338-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI-AVENTIS (FR) | 2011-04-07 | — | — | WO | disclosed |
| US-7906460-B2 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and “unnatural” UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER (US) | 2011-03-15 | — | — | US | disclosed |
| US-7820804-B2 | Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof | Sanofi-Aventia Deutschland GmbH (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20100267940-A1 | Method for Producing 4-Deoxy-4-Fluoro-D-Glucose Derivative | CENTRAL GLASS COMPANY, LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100261664-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| EP-2216337-A1 | METHOD FOR PRODUCING 4-DEOXY-4-FLUORO-D-GLUCOSE DERIVATIVE | Central Glass Company, Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-03-20 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| US-5474986-A | Galabiose derivatives modified at 3* and anomeric positions | SYMBICOM AKTIEBOLAG (SE) | 1995-12-12 | — | — | US | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| EP-0428605-B1 | SYNTHETIC RECEPTOR ANALOGUES | SYMBICOM AB (SE) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261664-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | UGGT1, SLC5A2, SLC5A1 | PTPN1 1721/4885USP2 3915/4885MEN1 1285/4885 |
| US-20100267940-A1 | Method for Producing 4-Deoxy-4-Fluoro-D-Glucose Derivative | SLC5A2, PFKFB3, PFKFB2 | PTPN1 2814/4885USP2 4072/4885MEN1 2171/4885 |
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | PNP, NUDT14, ENTPD5 | PTPN1 3074/4885USP2 3012/4885MEN1 3961/4885 |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SLC5A1, SLC5A2, SOST | PTPN1 895/4885USP2 4333/4885MEN1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.